Overview

A Study of SB939 in Patients With Translocation-Associated Recurrent/Metastatic Sarcomas

Status:
Completed
Trial end date:
2014-01-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effects a new drug SB939 has on you and your sarcoma. This research is being done because there is a need for better treatment options for advanced or recurring sarcoma. SB939 has been shown to shrink tumours in animals and some people and seems promising but it is not clear if it has any positive effects in sarcoma.
Phase:
Phase 2
Details
Lead Sponsor:
NCIC Clinical Trials Group
Collaborator:
S*BIO